72 results about "Pollakisuria" patented technology

Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

[Object] To provide a compound which can be used for the treatment of a disease associated with fatty acid amide hydrolase (FAAH), particularly urinary frequency, urinary incontinence and / or overactive bladder.[Means for solution] It is confirmed that a urea compound chemical-structurally characterized by having a piperidine or piperazine ring or a salt thereof has an excellent FAAH-inhibitory activity, and thus the present invention is completed. The urea compound or its pharmaceutically acceptable salt of the present invention can increase the effective bladder capacity and ameliorate the state of urinary frequency, and is therefore useful as an agent for treating urinary frequency, urinary incontinence and / or overactive bladder.

The present invention relates to a pharmaceutical composition for treatment and / or prevention for urinary diseases comprising a lysophosphatidic acid (LPA) receptor regulator.As LPA receptor regulators act on urethra and prostate, compounds acting on this receptor are useful in treating urinary diseases (urinary incontinence, dysuria, etc.). For example, an LPA receptor agonist useful for treatment of urinary incontinence, while an LPA receptor antagonist is useful for treatment of dysuria, ischuria, pollakiuria, nocturia, urodynia and benign prostatic hyperplasia.

Compounds having a high conductance-type of calcium-activated K channel opening effect and a smooth muscle relaxant effect for bladder based on the K-channel opening effect, which can be used in treating pollakiuria and urinary incontinence, are provided. 3,5-Dicyanopyridine derivatives or their salts.

The invention provides a morphinan derivative of the Formula (I): (wherein R1 is methyl, cyclopropylmethyl or the like; R2 and R3 are hydroxy, methoxy, acetoxy or the like; both Y and Z are valence bonds, —C(═O)— or the like; X is C2-C5 carbon chain (one of the carbon atoms may be substituted by oxygen, sulfur or nitrogen) constituting a part of the ring structure, or the like; (R4)k is substituted or non-substituted benzene fused ring, carbonyl group or the like; R9 is hydrogen or the like; R10 and R11 are bound to represent —O—, or the like, and R6 is hydrogen or the like) or a pharmaceutically acceptable acid addition salt thereof. The invention also provides a therapeutic or prophylactic agent for urinary frequency or urinary incontinence, comprising as an effective ingredient the morphinan derivative or the pharmaceutically acceptable acid addition salt thereof; a method for therapy or prophylaxis of the diseases.

(1) A preventive and / or a remedy for lower urinary tract diseases such as inflammation in the lower urinary tract, cystitis (interstitial cystitis, etc.) and urethritis; (2) an agent for improving bladder compliance and / or bladder capacity; and (3) an agent for protecting bladder mucosa and / or bladder epithelial cells and / or promoting the regeneration thereof; each containing an EP4 agonist. An EP4 agonist is useful in ameliorating symptoms of lower urinary tract diseases such as (1) frequent urination, (2) urgency of urination, (3) pain in the reproductive organs and / or lower urinary tract (for example, bladder pain, urinary tract pain, vulvar pain, vaginal pain, scrotal pain, perineal pain, pelvic pain, etc.) and / or (4) discomfort in the reproductive organs and / or lower urinary tract. Among all, a selective EP4 agonist is useful as a preventive and / or remedy for lower urinary tract diseases having no side effect.

The present invention provides one kind of Chinese medicine preparation for treating urinary system calculus and urinary tract infection and its preparation process. The Chinese medicine preparation has functions of clearing away heat, promoting diuresis, treating stranguria, diminishing inflammation, relieving pain and removing urinary calculus. It is used in treating urinary calculus, renal colic, urinary tract infection and other urinary tract diseases.

The invention relates to a pharmaceutical composition comprising a pyrrole derivative of the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate of either of them, as an active ingredient.(wherein R1 represents hydrogen or alkoxycarbonylamino, R2 represents alkyl, aryl which may be substituted, aromatic heterocyclyl which may be substituted, unsubstituted amino, monoalkylamino, dialkylamino, or cyclic amino which may be substituted; R3 represents cyano or carbamoyl; R4 represents hydrogen or alkyl; E represents alkylene; q is equal to 0 or 1, A represents methyl, aryl which may be substituted, or aromatic heterocyclyl which may be substituted)The pharmaceutical composition of the invention is effective for the treatment of pollakiuria or urinary incontinence.

A method of treating urinary incontinence, uncontrolled urination, and frequent urination in a human in need thereof is provided. The method includes placement of at least two calibrated, differential disturbances or protuberances under the human's feet.

To provide a therapeutic or prophylactic agent for frequent urination / strong urge to urinate or incontinence associated with overactive bladder, a lower urinary tract disease accompanied by a lower urinary tract pain such as interstitial cystitis and chronic prostatitis or a disease accompanied by a pain, which acts based on excellent trkA receptor-inhibiting activity. [MEANS FOR SOLVING PROBLEMS] Disclosed is a novel azolecarboxamide derivative having an azole ring (e.g., a thiazole or oxazole ring) bound to a benzene, pyridine or pyrimidine ring through a carboxamide. It is confirmed that the azolecarboxamide derivative has a potent trkA receptor-inhibiting activity. It is found that the azolecarboxamide derivative can be used as a very efficient, safe therapeutic or prophylactic agent for a lower urinary tract disease or a disease accompanied by a pain.

Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a solifenacin succinate-containing orally disintegrating tablet and a preparation method thereof. The orally disintegrating tablet is clinically used for treating symptoms such as frequent micturition, urgent urination and urinary incontinence caused by the overactive bladder.

An N-phenylarylsulfonylamide compound of formula (I) (R1 is COOH etc.; R2 is hydrogen, methyl, etc.; R3 and R4 are a combination of methyl and methyl, etc.; R5 is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin E2 receptor, especially an EP1 subtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and / or lower urinary tract disease syndrome or an antineoplastic agent.

The invention relates to a medicated wine for immunity enhancing and kidney nourishing and strengthening, which is made from soaking aweto, red common stonecrop herb, Epimedium, ginseng, snow lotuses, saffron, and superoxide dismutase in distillate spirits. The medicated wine has the advantages of improving blood circulation, enhancing immunity, cleaning up toxin, strengthening primordial energy, activating kidney power, replenishing essence and nourishing the marrow, enhancing the quality of sexual intercourse, and having obvious cure effects on pollakiuria patients, micturition urgency patients and prostatic hyperplasia patients without any toxic and side effects.

The invention discloses a novel medicinal use of the active parts of abelmoschus manihot general flavones, in particular use of the active parts of abelmoschus manihot general flavones in the preparation of medicaments for treating urinary tract infection including cystitis and urethritis. Abelmoschus manihot has the effects of disinhibiting water, dissipating stasis, dispersing swelling, detoxification and relieving common symptoms of urinary tract infection, such as frequent micturition, urgent urination, odynuria and unwell micturition. The active parts of abelmoschus manihot general flavones have excellent inhibiting effects on staphylococcus aureus, staphylococcus epidermidis and other gram-positive bacteria and negative bacteria, and have anti-inflammatory and pain-relieving effects and an obvious diuretic effect. Therefore, the active parts of abelmoschus manihot general flavones have excellent effects on the treatment of urinary tract infection, particularly chronic recurrent urinary tract infection.

The invention relates to a transdermal gel of oxybutynin or a pharmaceutically acceptable salt thereof used for treating overactive bladder with the symptoms of frequent urination, urgent urination and urinary incontinence, and a preparation method of the transdermal gel. The transdermal gel comprises oxybutynin or the pharmaceutically acceptable salt thereof, a gel matrix hydroxypropyl methylcellulose, a pH value regulator, a humectants and a solvent of anhydrous ethyl alcohol and water.

The invention relates to a medicament for treating vaginitis. The vaginitis is the most common infectious disease of women and the common symptoms thereof are vaginal secretions increase, pruritus vulvae and burning pain possibly accompanied by frequent urination, painful urination and dyspareunia. After a long-term research and clinical verifications, a traditional Chinese medicine for external use for treating vaginitis with better curative effect is finally found by the inventor. The dosage of the medicament compositions provided by the invention is also gained through a great deal of development of the inventor and the optimum proportion is as follow: 6 parts of radix sophorae flavescentis, 20 parts of rhizoma smilacis glabrae, 20 parts of stemona, 15 parts of radices sileris, 20 parts of belvedere fruit, 20 parts of fructus cnidii, 20 parts of cortex dictamni, 20 parts of golden cypress and 10 parts of schizonepeta. Each medicament functions to generate the synergistic effect by combining all, which has the effects of clearing heat and removing toxicity, killing parasites and relieving itching, and thus effectively treating vaginitis.

This invention relates to aryl or heteroaryl amido alkane derivatives of formula (I) in which Ar1 and Ar2 independently represent phenyl or a 5 or 6-membered heteroaromatic ring, R6 represents carboxyl or tetrazolyl, and the remaining variables are as defined in the text and claims, which are useful as an active ingredient of pharmaceutical preparations. The aryl or heteroaryl amido alkanes of the present invention have PGI2 antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with PGI2 activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension;hemophilia and hemorrhage; and inflammation, since the diseases also relate to PGI2.

The present invention relates to a phenyl or heteroaryl amino alkane derivatives which are useful as an active ingredient of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since the diseases also is alleviated by treatment with an IP receptor antagonist.

It is intended to provide a morphinan derivative represented by the following general formula (I): (I) wherein R<1> represents methyl, cyclopropylmethyl, etc.; R<2> and R<3> represent each hydroxy, methoxy, acetoxy, etc.; Y and Z represent each a valence bond, -(C=O)-, etc.; X represents a C2-5 carbon chain constituting a part of the cyclic structure (wherein one of the carbon atoms may be substituted by oxygen, sulfur or nitrogen); (R<4>)k represents an optionally substituted fused benzene ring, carbonyl, etc.; R<9> represents hydrogen, etc.; R<10> and R<11> may be bonded together to form -O-; and R<6> represents hydrogen, etc.The above-described compound is useful as a novel remedy or preventive for urinary frequency or urinary incontinence showing an isolated side effect. Moreover, it is useful in a method for treating or preventing the above diseases and utilization for these diseases.

The invention belongs to the technical field of medicaments, and in particular relates to a medicine for treating urinary tract infection. The main active component of the medicine disclosed by the invention is polysaccharide extracted from caryophyllaceae vaccaria segetalis (Neck.) Garcke. The polysaccharide in the invention is from vaccaria segetalis (Neck.) Garcke seeds. A method for preparingthe vaccaria segetalis (Neck.) Garcke polysaccharide and vaccaria segetalis (Neck.) Garcke polysaccharide medicine composition provided by the invention is simple and effective, and capable of being prepared into a variety of common oral forms, such as solid, liquid and the like. The medicine disclosed by the invention is mainly used for treating the urinary tract infection as well as frequent micturition, urgent urination and odynuria caused by diabetes. Compared with the traditional medicines, the medicine disclosed by the invention has an obvious curative effect, low recurrence rate and notoxic and side effects, and the product quality is stable and controllable.

[Object] To provide a therapeutic and / or prophylactic agent for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, based on an excellent trkA receptor inhibitory action.[Means for Solution] A novel azolecarboxamide compound in which a thiazole ring or an oxazole ring is bonded to a benzene ring, a pyridine ring, a pyridazine ring, a thiophene ring, a pyrazole ring or a pyrrole ring through carboxamide, or a salt thereof is confirmed to have a potent trkA receptor inhibitory activity, and found to be capable of being used as a therapeutic and / or prophylactic agent which is excellent in efficacy and safety for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, thereby completing the present invention.

The invention discloses a formula of a medicine composition with solifenacin and a preparation method of the tablet composition. The active component of the medicine composition is (1S)-(3R)-1-azabicyalo[2.2.2]oct-3-yl3,4-dihydro-l-phenyl-2-(1H)-isoquinoline carboxylic acid succinate (solifenacin). The preparation method includes the steps of smashing the active component and corresponding auxiliaries respectively, conducting physical mixing, conducting direct tabletting on dry powder, wrapping film coatings on tablets, and obtaining the medicine composition. The tablets can be used for treating or improving symptoms of overactive bladder including frequent micturition, urgent urination, acute urinary incontinence and other urinary tract symptoms.

The invention discloses a medicine composition which is mainly prepared from desmodium styracifolium, asiatic centella, oldenlandia diffusa, milk veteh, pyrrosia lingua, lygodium japonicum and giant knotweed. The medicine composition has the efficacy of clearing away heat and toxic materials as well as removing dampness and treating stranguria, and is used for stranguria, difficulty and pain in micturition and urinary tract infection which are caused by damp heat accumulation; and the adaptation diseases include frequent urination, urgent urination, dysuria, dark yellow urine and urinary tract infection. The medicine composition can be prepared into various oral liquid.

An N-phenylarylsulfonylamide compound of formula (I) (R1 is COOH etc.; R2 is hydrogen, methyl, etc.; R3 and R4 are a combination of methyl and methyl, etc.; R5 is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin E2 receptor, especially an EP1 subtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and / or lower urinary tract disease syndrome or an antineoplastic agent.

An optically active form of the quinazolinone derivatives represented by the general formula (1): [wherein Y represents a phenyl group or C2-C7 alkyl group; E represents —CH═ or nitrogen atom; and R represents a C1-C4 alkyl group and so on], or pharmaceutically acceptable salts thereof, has a selective antagonism for the M3 muscarinic receptor and depressant action on the frequency of rhythmic bladder contractions, and it is useful for the treatment of pollakiuria and urinary incontinence.

A pharmaceutical composition comprising (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide or a pharmaceutically acceptable salt thereof and (3R)-quinuclidin-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate or a pharmaceutically acceptable salt thereof, as active ingredients, in particular for improving various symptoms accompanying overactive bladder, such as urinary urgency, pollakiuria and / or urinary incontinence.

A Chinese herbal medicine preparation for treating prostatic swelling or hypertrophy in middle-aged and elderly people is a Chinese herbal medicine compound decocted tea and a water pill or a big honeyed pill or granule or a granulated tea bag preparation which comprises herbs of radix astragali, angelica, sophora flavescens, Zhejiang fritillary bulbs, licorice, desmodium triquetrum, and mirabilis jalapa, an adhesive of glutinous rice or a honey ingredient, and a packaging material. The medicinal material resource is rich; the preparation and process of the medicine are easy; the medicine is convenient for taking, strong in targeting effect, good in curative effect, and has no toxic or side effect. The invention is applicable to prevention, health care, conditioning, and health preservation, can perform treatment by penetrating into the prostate cyst membrane of a suitable human body of middle-aged and elderly people, has the advantage and characteristic of a high total effective rate in treating diseases such as male acute and chronic prostatic swelling or hypertrophy, and resulted complications of urgency of urination, frequency of urination, urodynia, urinary stoppage, guttate emiction, and the like, and fills the gap of the core technical field by providing an innovative prescription formula which performs treatment by penetrating into the prostate cyst membrane to treat male acute and chronic prostatic swelling or hypertrophy, and resulted complications.

The invention relates to a traditional Chinese medicine composition for treating frequent urination, urgent urination and painful urination caused by hyperplasia of prostate. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 5-25 parts of gardenia jasminoides ellis, 5-20 parts of cimicifuga foetida, 5-25 parts of polygonum aviculare, 5-20 parts of scutellaria baicalensis, 5-25 parts of fringed pink, 10-30 parts of rehmannia glutinosa libosch, 5-20 parts of rhizoma alismatis, 5-25 parts of golden cypress, 5-25 parts of bamboo leaf, 5-20 parts of medicinal cyathula root, 5-25 parts of radix scrophulariae, 5-20 parts of pericarpium citri reticulatae, 5-25 parts of yam rhizome, 10-30 parts of rhizoma atractylodis macrocephalae, 5-25 parts of rhizoma corydalis, 5-25 parts of pyrrosia lingua, 5-20 parts of codonopsis pilosula, 5-25 parts of eucommia ulmoides and 5-15 parts of liquorice. The traditional Chinese medicine composition has the effects of nourishing liver and kidney, clearing away heat and drying dampness, purging fire, removing toxin, nourishing yin, promoting the secretion of saliva or body fluid, and activating blood circulation to dissipate blood stasis. By utilizing the traditional Chinese medicine composition, effects for treating the frequent urination, urgent urination and painful urination caused by the benign prostatic hyperplasia are significant, and the effect is reliable.

The invention discloses a health food composition capable of improving frequent urination and urinary incontinence of females as well as a preparation method and an application thereof and belongs to the technical field of health foods. The composition is mainly prepared from the following raw material components in parts by weight: 0.4-5 parts of pumpkin seed oil, 0.4-4 parts of pumpkin seed aqueous extract, 15-30 parts of rhizoma dioscoreae, 0.6-3 parts of fructus alpiniae oxyphyllae aqueous extract, 0.4-5 parts of summer squash seed oil, 0.4-5 parts of summer squash seed aqueous extract, 0.5-3 parts of radix angelicae sinensis aqueous extract and 0.5-2 parts of concha ostreae. According to the health food composition capable of improving frequent urination and urinary incontinence of females as well as the preparation method and the application thereof, a special extraction method is adopted; the health food composition is high in utilization rate of effective components, low in waste, excellent in effect and free of toxic and side effects.